Cantor Fitzgerald upgraded Omeros to Overweight for Omeros stock

Published on 10/08/2026 at 13:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit USD 28.53 million versus USD 12.69 million consensus. Omeros stock costs EUR 16.95 on October 8, 2026 versus EUR 16.75.

OMER, US6821431029, Illustration mit AI erstellt.

Omeros Corporation (ISIN US6821431029) was trading at EUR 16.95 at Lang & Schwarz on October 8, 2026 at 1:09 p.m. CEST, plus 1.19 percent. According to Markets Insider on September 22, 2026, Cantor Fitzgerald upgraded Omeros from Neutral to Overweight and set a USD 22.00 price target.

Cantor saw stronger launch potential

The rating change followed physician feedback on Yartemlea, Omeros's approved treatment for stem-cell transplant-associated thrombotic microangiopathy. Markets Insider reported that Cantor Fitzgerald projected a potential 30 percent to 40 percent market share over time and raised its peak sales estimate to USD 400.00 million.

That forecast gives the analyst action a commercial rather than purely clinical basis. The key test is whether Yartemlea can convert early physician support into repeat prescriptions and cash generation.

Revenue beat expectations in the second quarter

MarketBeat reported that Omeros generated USD 28.53 million of revenue in the second quarter of 2026, versus USD 12.69 million consensus. Earnings per share reached USD 0.02, compared with a consensus loss of USD 0.27.

The revenue comparison is the clearest operating figure in the current picture: actual sales were USD 15.84 million above consensus, while earnings per share were USD 0.29 better than expected. The figures point to a commercial launch that materially changed the quarterly revenue base.

Stock remains below its yearly high

Omeros had a market capitalization of USD 1.4 billion and a 52-week range of USD 4.06 to USD 21.24 as of October 7, 2026. The Lang & Schwarz euro quote therefore remained below the latest reported Nasdaq range in a different currency, so the two price references are not combined into one distance calculation.

Price holds above the prior close

Omeros was trading at EUR 16.95 at Lang & Schwarz on October 8, 2026 at 1:09 p.m. CEST, up 1.19 percent versus the prior close of EUR 16.75. The primary listing is Nasdaq, where the October 7, 2026 reference price was USD 18.75 at 4:00 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Omeros stock.